prasugrel

A novel platelet inhibitor approved for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. Prasugrel… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2017
010020020032017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
BACKGROUND The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST… (More)
  • table 1
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Mechanical reperfusion with stenting for ST-elevation myocardial infarction (STEMI) is supported by dual antiplatelet… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Both clopidogrel and prasugrel require biotransformation to active metabolites by cytochrome P450 (CYP) enzymes. Among… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • table 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Patients with diabetes mellitus (DM) are at high risk for recurrent cardiovascular events after acute coronary… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
AIMS P2Y(12) receptor antagonism and platelet inhibition by prasugrel vs. clopidogrel were investigated in patients with stable… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
From Brigham and Women’s Hospital and Harvard Medical School, Boston (S.D.W., E.B., C.H.M., S.A.M., C.M.G., E.M.A.); Institut de… (More)
  • table 1
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND The increasing use of higher-than-approved doses of clopidogrel in clinical practice is based in part on the desire… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Thienopyridines are metabolized to active metabolites that irreversibly inhibit the platelet P2Y(12) adenosine… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND The aim of this study was to compare rate of onset, magnitude, and consistency of platelet inhibition after… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
AIMS This study was designed to compare the degree of inhibition of platelet aggregation (IPA) of prasugrel with that of… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?